New York, Feb 18, 2026, 10:03 AM EST — Regular session
- Liquidia shares picked up roughly 2% in early trade, clawing back a bit after they tumbled 11% the previous day.
- Tuesday’s options flow leaned bearish; traders snapped up puts in size.
- Liquidia’s audited full-year numbers are due out later this month, and investors are also keeping a close eye on developments in its ongoing patent dispute.
Liquidia Corp stock bounced 2.2% higher to $34.59 early Wednesday, recovering part of the previous session’s sharp drop. Shares moved in a range from $33.93 to $35.15.
Tuesday’s 11.4% slide to $33.84 yanked Liquidia back into focus for traders, especially after its wild ride in February. The bounce comes right on the heels of that drop. (Yahoo Finance)
This is a sensitive stretch for Liquidia. Minor developments carry extra weight as the company pushes forward with its inhaled treprostinil product, still in the early commercial phase. Investors are already watching for the upcoming full financial update.
Derivatives were a pressure point. According to MarketBeat, traders picked up 22,447 put options on Tuesday—contracts allowing holders to sell at a fixed price. That’s a surge, about 84% higher than normal volume. (MarketBeat)
Last month, Liquidia put out an early, unaudited read on 2025 YUTREPIA net sales, coming in around $148.3 million. The company expects to release audited numbers in February. CEO Roger Jeffs called it “a transformational year” for Liquidia, citing the commercial debut of YUTREPIA. (GlobeNewswire)
Liquidia calls Morrisville, North Carolina home. The company focuses on therapies for rare cardiopulmonary conditions—pulmonary arterial hypertension and pulmonary hypertension tied to interstitial lung disease, its profile shows. (Reuters)
Still, the wild card for the stock isn’t showing up on the income statement. Liquidia has acknowledged that its future with YUTREPIA depends on active litigation against United Therapeutics, which is pushing for an injunction that could halt sales for either or both uses. (SEC)
Traders are eyeing Wednesday’s rebound to see if it sticks through the close, while also keeping tabs on whether options positioning remains defensive. With February options on the shares expiring Feb. 20, day-to-day price swings could get choppy. (Yahoo Finance)
